How Your Liver Affects a New Drug Called VC005
Treatments studied
This study tests how a new medication (VC005) moves through your body, with a focus on how liver health affects this process. Researchers will compare people with normal liver function to those with liver problems to understand if the drug is safe and works properly in both groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old
- You weigh at least 50 kg (110 lbs) if male, or 45 kg (99 lbs) if female, with a healthy BMI (roughly 18–32)
- You cannot be pregnant, planning pregnancy, or nursing for 3 months after the last dose; you must use reliable contraception
- No history of serious allergies to drugs or foods, and no known allergy to VC005
- No active infections, recent blood donation (within 3 months), heavy smoking (more than 5 cigarettes daily), or alcohol abuse
- No history of severe liver or kidney disease, difficulty swallowing, or recent stomach/bowel problems that affect how your body absorbs medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how food changes the way your body processes a new medicine called VV119. It helps make sure the drug works safely and effectively. Healthy adults are needed to participate.
This study tests how eating food changes how your body absorbs a new experimental drug called VV913. Researchers will give you the drug with and without food to see if meals make a difference in how well it works.
This trial tests a new tablet called VV261 in healthy volunteers to see how safe it is and how the body processes it. It is an early study to gather important information before larger trials.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how the body processes and tolerates a new experimental drug (MDR-001) in people with mild to moderate liver disease. The research helps doctors understand if the drug is safe and how it works when liver function is reduced.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
Hear when a new Hepatic Impairment and Healthy Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.